Loading...
•
Dec 31, 2021
RAPT Q4 2021 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2021.
Key Takeaways
RAPT Therapeutics reported a net loss of $17.9 million for the fourth quarter of 2021, compared to a net loss of $12.7 million for the fourth quarter of 2020. The company's cash, cash equivalents and marketable securities totaled $189.7 million as of December 31, 2021.
RPT193 Phase 1b clinical trial in atopic dermatitis showed positive results.
Phase 2b clinical trial of RPT193 in atopic dermatitis is planned for the first half of 2022.
Phase 2a trial in asthma is planned for RPT193 in the second half of 2022.
FLX475 development is continuing in several indications including EBV+ lymphoma, nasopharyngeal cancer and head and neck cancer.
RAPT
RAPT
Forward Guidance
RAPT plans to initiate a Phase 2b clinical trial of RPT193 in atopic dermatitis in the first half of 2022, as well as a Phase 2a trial in asthma in the second half of the year. They also plan to provide an update on FLX475 in 2022 when they have data that are sufficiently mature from the ongoing cohorts.
Positive Outlook
- Initiate a Phase 2b clinical trial of RPT193 in atopic dermatitis in the first half of 2022.
- Initiate a Phase 2a trial in asthma in the second half of the year.
- Provide an update on FLX475 in 2022 when data are sufficiently mature.
- Advance two unique drug candidates, RPT193 and FLX475.
- Pursue a range of targets that are in the discovery stage of development.
Challenges Ahead
- Clinical development progress is subject to risks and uncertainties.
- Timing of results from clinical trials of FLX475 and RPT193 is uncertain.
- Actual results may differ materially from the results expressed or implied by forward-looking statements.
- Forward-looking statements are based only on current information, assumptions and expectations.
- RAPT disclaims any obligation to update these forward-looking statements.